Amylin Pharmaceuticals Announces BYETTA Revenue
January 26 2006 - 6:30AM
PR Newswire (US)
Preliminary Fourth Quarter 2005 Results SAN DIEGO, Jan. 26
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN) today announced that unaudited net product sales for
BYETTA(R) (exenatide) injection for the quarter ended December 31,
2005 were approximately $49 million. BYETTA net product sales
consist of shipments to the Company's wholesale customers, net of
allowances for discounts, distribution fees and returns. These
preliminary results are being released in conjunction with today's
financial results announced by Eli Lilly and Company, Amylin's
collaborative partner for BYETTA. Amylin also announced that the
unaudited net loss for the quarter ended December 31, 2005 is
expected to be $66 to $69 million, or $0.60 to $0.63 per share.
Amylin's fourth quarter activities included increased investment in
exenatide LAR (once-weekly formulation of BYETTA) and other
compounds in the Company's drug development pipeline, and increased
selling, general and administrative expenses. Amylin plans to
release full financial results for the fourth quarter and year
ended December 31, 2005 on Thursday, February 9, 2006, at the close
of market, followed by a webcast of the Company's Quarterly Update
Conference Call at 5:00 p.m. ET/2:00 p.m. PT. During the call, the
Company plans to provide supporting details underlying its fourth
quarter and 2005 financial results, and information regarding key
trends and assumptions for 2006 operations. About Amylin Amylin
Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. This press release
contains forward-looking statements about Amylin, which involve
risks and uncertainties. The Company's actual results could differ
materially from those discussed herein due to a number of risks and
uncertainties, including risks that the Company's final audited
results for the fourth quarter of fiscal 2005 could differ
materially from those described above as a result of the Company's
customary quarterly financial closing procedures. These and
additional risks and uncertainties are described more fully in the
Company's most recently filed SEC documents, including its Form
10-Qs. Amylin disclaims any obligation to update these
forward-looking statements. DATASOURCE: Amylin Pharmaceuticals,
Inc. CONTACT: Mark Foletta, VP, Finance and CFO of Amylin
Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024